Saturday 17 October 2026 Export JYNT’s income statement to Excel — free account

The Joint Corp.

In the quarter to June 2026, revenue grew 14.4%, EPS grew 400.0% and free cash flow grew 432.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.03 0.12 +1.74%

Follow JYNT

Alert me

Market cap: $97.7M
P/E: 26.0×
Fwd P/E: 16.9×
Dividend yield: —
F-score: 7/9
Altman Z: 2.39
Beneish M: −2.27
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.98

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	3	2	2	—	1	1	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 16.81%

Capital & Financial Ratios $m

Market Cap 97.73

Revenue 58.55

Net Income 3.80

Free Cash Flow 4.23

Net Debt (23.00)

Current Ratio 1.83

Debt/Equity 0.00

P/E ratio 26.04

Fwd P/E 16.90

P/S ratio 1.71

P/B ratio 6.31

Past 5Y EPS Growth (26.73%)

This Y EPS Growth 1,300.00%

Next Y EPS Growth 63.89%

Next Y revenue growth 10.94%

Next 5Y EPS Growth 25.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 0.34%

10-year low 10-year high

P/S against its own 10 years 6.53%

10-year low 10-year high

P/B against its own 10 years 20.35%

10-year low 10-year high

EV/Sales against its own 10 years 5.96%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	19	26	24	23
Receivables	3	3	3	2
Inventory	—	—	—	—
Other	—	—	—	—
	44	75	52	44

	2023	2024	2025	Q'26
Payables	1	2	2	1
ST’ Debt	—	—	—	—
Other	3	5	6	4
	34	49	33	24

Compound Annual Growth %

	10y	5y	3y
Sales	14.78%	(1.33%)	(18.46%)
Cash Flow	0.00%	(30.31%)	(39.27%)
Earnings	0.00%	(26.07%)	66.78%
Book Value	(3.11%)	(6.52%)	(22.65%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15	15	—	—	—
’25	13	13	13	15	55
’24	12	13	13	15	52
’23	28	29	29	—	47
’22	22	25	26	28	101
’21	18	20	21	21	80
’20	14	13	15	17	59

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	2	—	—	—
’25	(4)	1	2	3	2
’24	3	(1)	3	4	9
’23	6	1	4	3	15
’22	0	(1)	4	5	8
’21	2	7	3	1	14
’20	1	2	4	4	11

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	2	—	—	—
’25	(4)	0	1	3	0
’24	2	(1)	3	4	8
’23	5	0	3	2	10
’22	(1)	(6)	0	3	2
’21	0	4	1	0	7
’20	0	1	4	2	7

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.09	0.05	—	—	—
’25	0.05	0.01	0.06	0.07	0.19
’24	0.06	(0.24)	(0.21)	(0.18)	(0.56)
’23	0.15	(0.02)	(0.05)	(0.75)	(0.65)
’22	0.00	(0.06)	0.05	0.04	0.04
’21	0.16	0.18	0.13	0.04	0.48
’20	0.06	0.01	0.11	0.72	0.90

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.85	2.48	4.67	7.88	7.67	26.28	12.85	7.31	8.88	7.50	Analyst estimates 2026–2028 Powerpack
	High	5.89	6.00	9.64	21.80	27.91	111.06	66.42	20.00	17.82	13.47
People
People	Employees	94	148	138	150	425	601	781	794	736	330
	Revenue/emp, $m	0.22	0.17	0.27	0.32	0.14	0.13	0.13	0.06	0.07	0.17
Income, $m
Income, $m	Revenue	21	25	37	48	59	80	101	47	52	55
	Gross margin, %	85.68	87.06	88.24	88.51	88.91	90.42	90.94	77.69	77.92	79.55
	EBT	(15)	(3)	0	3	5	6	1	0	(2)	0
	EBT margin, %	(73.13)	(13.63)	0.30	6.96	9.22	7.57	0.69	0.54	(3.08)	(0.42)
	Net income	(15)	(3)	0	3	13	8	1	(10)	(6)	3
	Depreciation	3	2	2	2	3	4	7	9	5	2
Per share, $
Per share, $	Revenue	1.62	1.88	2.68	3.51	4.19	5.59	6.99	3.20	3.50	3.63
	Earnings	(1.20)	(0.25)	0.01	0.24	0.94	0.50	0.04	(0.66)	(0.57)	0.19
	Cash flow	(0.85)	(0.01)	0.40	0.54	0.80	0.97	0.57	1.00	0.63	0.12
	Capex	(0.15)	(0.03)	(0.08)	(0.30)	(0.30)	(0.49)	(0.41)	(0.34)	(0.08)	(0.10)
	Free cash flow	(1.00)	(0.04)	0.32	0.24	0.50	0.48	0.16	0.66	0.55	0.02
	Book value	0.55	0.09	0.05	0.41	1.51	2.12	2.25	1.69	1.39	1.00
	Shares, m	13	13	14	14	14	14	14	15	15	15
Valuation, ×
Valuation, ×	P/E	0.00	0.00	770.37	70.17	28.24	125.70	451.48	0.00	0.00	45.89
	P/S	1.64	2.60	3.10	4.60	6.27	11.76	1.97	2.95	3.04	2.40
	P/B	4.86	56.27	156.30	38.99	17.41	31.04	6.12	5.60	7.67	8.75
	EV/Sales	1.48	2.47	2.89	4.47	5.99	11.56	1.91	2.63	2.58	2.00
	EV/FCF	(2.39)	(72.59)	26.38	90.43	62.54	169.20	(65.11)	28.07	45.56	(22.20)
Cash, $m
Cash, $m	Operating cash flow	(11)	0	5	8	11	14	8	15	9	2
	Capex	(2)	0	(1)	(4)	(4)	(7)	(6)	(5)	(1)	(2)
	Free cash flow	(13)	(1)	4	3	7	7	2	10	8	0
Balance, $m
Balance, $m	Working capital	0	1	1	0	7	5	(6)	11	26	19
	Total debt	0	1	1	2	5	2	2	2	—	—
	Net debt	(3)	(3)	(8)	(6)	(16)	(18)	(8)	(17)	(26)	(24)
	Shareholders’ equity	7	1	1	6	21	30	33	25	21	15
Returns, %
Returns, %	ROA	(60.19)	(19.34)	0.70	9.90	24.03	9.89	0.69	(10.79)	(6.81)	4.03
	ROIC	(239.74)	0.00	0.00	0.00	66.43	30.67	2.15	2.63	0.00	0.00
	ROE	(109.94)	(84.97)	15.60	103.09	98.09	29.42	1.99	(34.00)	(25.51)	16.26

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AUNA Auna S.A.	$392.3M	76.0×	5.2×	+20.51% (above 0%: growing)	−61.29% (below 0%: shrinking)	+121.08% (above 0%: growing)	35.72%	13.09%	Compare
SRTA Strata Critical Medical, Inc.	$384.0M	9.0×	— (loss-making)	+60.74% (above 0%: growing)	n/m	+150.33% (above 0%: growing)	20.98%	(7.46%)	Compare
AIRS AirSculpt Technologies, Inc.	$102.0M	— (loss-making)	— (loss-making)	−2.53% (below 0%: shrinking)	n/m	−131.07% (below 0%: shrinking)	61.38%	(0.07%)	Compare
JYNT The Joint Corp.	$97.7M	26.0×	16.9×	+14.41% (above 0%: growing)	+400.00% (above 0%: growing)	+432.31% (above 0%: growing)	83.68%	(2.43%)
PARK Park Dental Partners, Inc.	$91.3M	— (loss-making)	—	+12.15% (above 0%: growing)	−65.84% (below 0%: shrinking)	−34.78% (below 0%: shrinking)	14.37%	1.90%	Compare
BTMD biote Corp.	$39.9M	6.8×	11.0×	−9.48% (below 0%: shrinking)	n/m	−174.16% (below 0%: shrinking)	65.38%	(7.93%)	Compare
PIII P3 Health Partners Inc.	$30.1M	— (loss-making)	—	+8.60% (above 0%: growing)	n/m	−272.24% (below 0%: shrinking)	22.26%	10.67%	Compare
CCEL Cryo-Cell International Inc.	$29.4M	— (loss-making)	43.8×	−0.02% (below 0%: shrinking)	+77.78% (above 0%: growing)	−58.37% (below 0%: shrinking)	79.38%	28.04%	Compare
DCGO DocGo Inc.	$27.9M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−132.28% (below 0%: shrinking)	30.52%	(24.41%)	Compare
Median of peers	$65.6M	9.0×	11.0×	+4.29%	−61.29%	−94.72%	33.12%	0.92%

All 55 Medical Care Facilities stocks →

The Joint Corp. (JYNT) key facts

The Joint Corp. (JYNT) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, JYNT traded at $7.03, a market capitalization of $97.7 million.
Return on equity was 16.3% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 2.39 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.